Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...

Bloomfield Hills internal medicine physician Amjad Rass was excited to reunite with family in Syria last month for the first ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Orlando Health Orlando Regional Medical Center has debuted its redesigned emergency room downtown. The nonprofit health ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...